7th Annual Oligo Networking Event , Roche Innovation Center, Dienstag, 26. März 2019

 
7th Annual Oligo Networking Event – Celebrating oligos becoming a therapeutic reality
Developed by the community for the community
 
Roche Basel, Tuesday 26 - Wednesday 27 March 2019
 
sponsored by:                                 
 
 
Roche and GE Healthcare Life Sciences, in partnership with GSK, AstraZeneca, University of Oxford and BioMax are pleased to invite you to their seventh oligonucleotide networking event. The title of this year's event is "Celebrating oligos becoming a therapeutic reality". This two day meeting is kindly being hosted by Roche at their facility in Basel and is free to attend.
The themes covered in the 2019 meeting will include:

Conjugation
Long mRNA therapies
Solid phase v liquid phase synthesis
Green chemistry
Medicinal chemistry
Commercialisation of oligonucleotides
Case studies of approved oligonucleotides

The meeting aims to bring together the community of interested professionals and practitioners in industry and academia to network, discuss the latest developments in this field, explore knowledge transfer issues and share best practise.
GE Healthcare Life Sciences offers tools and support to take oligonucleotides from research, through process development, to full-scale manufacturing. A skilled and dedicated service organization provides instrument service, technical application support, training and education through Fast Trak Design™, and professional services such as Smart Asset Management Services (SAMS) and Validation Services.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. 
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit
supported by:  

Dienstag, 26. März 2019, Roche Innovation Center, 7th Annual Oligo Networking Event

Weitere interessante Veranstaltungen
Holen Event Empfehlungen basierend auf Ihre Facebook-Geschmack. Hol es dir jetzt!Zeigen Sie mir die passenden Veranstaltungen für michNicht jetzt